Cargando…
Uptake of hepatitis C direct-acting antiviral treatment in China: a retrospective study from 2017 to 2021
BACKGROUND: Direct-acting antivirals (DAAs) for hepatitis C treatment in China became available since 2017. This study expects to generate evidence to inform decision-making in a nationwide scale-up of DAA treatment in China. METHODS: We described the number of standard DAA treatment at both nationa...
Autores principales: | Du, Xinyu, Mi, Jiarun, Cheng, Hanchao, Song, Yuanyuan, Li, Yuchang, Sun, Jing, Chan, Polin, Chen, Zhongdan, Luo, Simon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043849/ https://www.ncbi.nlm.nih.gov/pubmed/36978198 http://dx.doi.org/10.1186/s40249-023-01081-4 |
Ejemplares similares
-
Eliminate Hepatitis C as a Public Health Threat: A Narrative Review of Strategies, Gaps, and Opportunities for China
por: Song, Yuanyuan, et al.
Publicado: (2022) -
Reported adverse events related to use of hepatitis C virus direct-acting antivirals with opioids: 2017–2021
por: Martinez, Anthony, et al.
Publicado: (2023) -
Disparities in direct acting antivirals uptake in HIV‐hepatitis C co‐infected populations in Canada
por: Saeed, Sahar, et al.
Publicado: (2017) -
Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis
por: Karayiannis, Peter
Publicado: (2012) -
Direct-acting antiviral retreatment patterns for hepatitis C
por: Hasan, Shaquib Al, et al.
Publicado: (2022)